Thanks so much, Jens. Let me just first start with a reminder of why Fostrox is different. This is an oral prodrug that is activated in the liver, which means that we deliver the active substance, which is troxacitabine, where the tumor is and keeps systemic exposure low. I know we have said this before, but this is really important. And this is confirmed also by the biopsies from our study, where we can see DNA damage in the tumor tissue and no DNA damage in the surrounding healthy liver tissue. That really translates into what we see clinically. In combination with Lenvatinib, we see efficacy substantially beyond what has been reported in second-line HCC, including in the recently presented IMbrave251 study with atezolizumab and bevacizumab refractory patients. And we see a combination with our drug that is really well tolerated. The final data from our study were published, as just mentioned, in Clinical Cancer Research in June this year. Our strategic focus remains unchanged. There is still no approved treatment in second-line advanced liver cancer. That is a first-to-market opportunity in a market worth more than $2.5 billion annually. And I know that we are coming back a little bit to that in the summary from Jens. And this is why the FLEX-HCC study that is ongoing in Korea is now our highest clinical priority for the moment.
So next slide. A few words on the publication itself, because it is an important milestone for this program. The full safety and efficacy data set from the phase 1b/2a study is now published in the peer-reviewed Journal of Clinical Cancer Research and Professor John J. Chong, who is also our primary investigator in the FLEX-HCC study, is the first author. The clinical message I would emphasize is the one that you can see in this title: tumor control without deterioration of liver function. In many other tumor types, it is the metastatic disease. I am sure you are all aware of this. It is the metastatic disease that drives mortality. In HCC, patients most often die from liver decompensation, and it is frequently caused by local tumor progression. So the treatment goal is to control the tumor in the liver without compromising the liver function. And that is a balance most systemic therapies struggle with. What you see in the figures here are the liver function parameters during the full treatment time. It is transaminase and the ALBI score where you measure liver function, and across the treatment cycles, all of these parameters remain stable over time. In other words, we achieve tumor control without deterioration of liver function. And that is what keeps patients fit enough not only to continue the treatment in this case, the study, but also to receive subsequent therapy. Next slide. I would also like to comment on the IMbrave251 study that was presented at ASCO this year. Because it is highly relevant for how we think about the second line. This study was large. It was over 550 patients asking whether it makes sense to continue immunotherapy after progression on an immunotherapy. Note that if you press one more time, you will see that. Note how favorable the patient population was. The patient had to receive at least four cycles of atezolizumab plus bevacizumab as prior treatment. And on that prior treatment, they needed to have documented disease control, meaning stable disease, partial response, or complete response on at least two tumor assessments. In other words, these patients who had done well on the first treatment are the patients who were included here. And even in that selected population, adding continued immunotherapy to a TKI yielded no benefit. In this case, Lenvatinib gave no benefit, neither in the overall survival nor in the progression-free survival, and the response rate remained below 8%. For us, the conclusion is clear: continuing immunotherapy is not the answer. After immunotherapy failure, the second line remains open and what is needed is a new mechanism of action. And that is precisely where Fostrox is positioned.
You can go to the next slide. Against that background, let me mention our own efficacy data. In this context. It looks a little bit different than what we have shown before, but it is also intended to show, in the context of IMbrave251, that more than 75% of the patients treated with Fostrox plus Lenvatinib experienced tumor shrinkage, and the objective response rate was 24%. We had a time to progression. I know Jens already said that of 10.9 months and the median duration of response was more than seven months. And we actually see that the longest response is still ongoing beyond 36 months. And the part of this figure that might be interesting, again, in the context of IMbrave251, is the color coding on this figure. The orange bars are the patients who were primary refractory on their prior therapy. In other words, those who never responded to first-line treatment in this study also had tumor reduction. Patients benefited from Fostrox largely independent of how they responded in the previous line, which is not what we usually see in this setting. And it speaks to a generally different mechanism that is needed in the post-immunotherapy setting. This is the data set that gives us the confidence to run this randomized comparison. And that is the FLEX-HCC study.
Go to the next slide. And this is the study design for this study. It is a study of 80 patients with advanced second-line hepatocellular carcinoma, all with one prior immunotherapy regimen. And they have a preserved liver function and good performance status. They are randomized 1 to 1 between Fostrox plus Lenvatinib or Lenvatinib alone. The primary endpoint for this study is objective response rate assessed by a blinded independent central review. We also look at duration of response. We also look at the duration of response. Progression-free survival. Overall survival. Safety. A secondary endpoint is also included, and tumor assessment is performed by CT or MRI every six weeks. The study is run with the Korean Cancer Study Group across 12 hospitals. As I mentioned before, Professor Chan is the principal investigator. The first patient in this study was dosed in May, and the enrollment is progressing well and very much in line with our plan to include all patients within 12 months. And we expect topline results from this study in the second half of 2027.
There are two things that make this design attractive. We generate robust comparative data through an established research consortium, and the design allows for rapid readout. So, let me just move into MIV-711, our Cathepsin K inhibitor. As Jens said, we are now developing this drug or this molecule into two rare bone indications. Both these diseases are driven by excessive bone resorption. And in both, there is no approved drug treatment today. I will start with Perthes disease. So, Perthes disease or it is also called Legg-Calvé-Perthes disease. It affects around 1 in 1,500 children, most often boys, most often between 4 and 8 years of age. So relatively early. What happens is that for unknown reasons, the blood supply to the femoral head is suddenly disrupted. What happens is that the bone dies. And because the dead bone is then resorbed faster than new bone can be formed. The effect of that is that the femoral head collapses and deforms while the child continues to walk and put weight on the femoral head. Today, we have no disease-modifying medication to offer to these children. What is used is bracing and surgery, and it addresses only the acute symptoms. But they do not change the underlying process, and the majority are left with permanent damage to the hip; most develop debilitating osteoarthritis as adults, and around 20% will need a total hip replacement later on, or actually earlier on, because it happens sooner than it does in the normal population. So this is a disease where the mechanism is well understood, where the need is severe and where, as I said, there are no disease-modifying treatments. That is exactly the type of situation where MIV-711 can make a difference. To explain what happened and where MIV-711 comes in, and how and when to intervene in this disease, Legg-Calvé-Perthes disease progresses through four stages. Legg-Calvé-Perthes disease is caused by the blood supply loss to the femoral head. First, it is the necrosis, then fragmentation, then reossification, and finally the remodeling of the femoral head, and Cathepsin K is the key process driving this bone resorption. So by inhibiting Cathepsin K, we aim to slow the resorption and preserve the shape of the femoral head before severe fragmentation has occurred, which points us to the stage 1 to 2a that you can see on this slide, and it is consistent with the effect we have demonstrated in the disease-specific animal model that we have conducted. Good news is that these children present early. And why is that? It is because they have pain and they start limping, which brings them to medical care quickly. And the Swedish registry data shows that around 80% are diagnosed in stage 1 or 2A, so the population we can treat at diagnosis is around 60% to 80% of all patients, and that is not a small subset.
With that, I will hand back to Jens.